FF-10502

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FF-10502 

FF-10502 是 Gemcitabine 的结构类似物，是一种嘧啶核苷抗代谢物。FF-10502 抑制 DNA 聚合酶 α 和 β (DNA polymerase α/β)。FF-10502 通过对休眠细胞的作用机制显示出有益的抗癌活性。

FF-10502

FF-10502 Chemical Structure

CAS No. : 184302-49-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells[1].

体外研究
(In Vitro)

FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC50s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Human pancreatic cancer cell lines (BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2)
Concentration: 0.1 nM to 10 μM
Incubation Time: 72 hours
Result: Inhibited the growth of pancreatic cancer cell lines.

体内研究
(In Vivo)

FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1].
Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg
Administration: Tail vein injection; once weekly; for 4 weeks
Result: Suppressed tumor growth in a dose-dependent manner in mice.

分子量

261.27

Formula

C9H12FN3O3S
CAS 号

184302-49-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务